Click below to learn more about the use of CYP2C9 genetics in the prescribing of certain NSAIDs, including celecoxib, ibuprofen, meloxicam, and piroxicam.
Celecoxib, ibuprofen, meloxicam, and piroxicam are metabolized by the liver to inactive metabolites. The protein in the liver responsible for the majority of this metabolism is the cytochrome p450 enzyme CYP2C9 (pronounced "sip two see nine").
Across populations, CYP2C9 protein alleles can have different genetic variants that impact their ability to metabolize NSAIDs and other medications. The different alleles can produce three different metabolism phenotypes: normal, intermediate, and poor metabolizers. Of these, the intermediate and poor metabolizer phenotypes have been shown to have higher drug levels and increased risk of adverse effects.
At UCHealth the use of pharmacogenetics when prescribing certain NSAIDs will occur in patients who meet the following conditions:
Provided a blood or saliva sample to the Colorado Center for Personalized Medicine (CCPM) Biobank laboratory and this sample has undergone genotyping.
Have consented for return of their results.
Are prescribed celecoxib, ibuprofen, meloxicam, or piroxicam.
This process takes a minimum of 4-6 weeks but may take several years. Therefore, results will not be available at initial presentation if a patient has not previously enrolled in the Biobank.
If you are a provider AND your patient is a CYP2C9 intermediate or poor metabolizer, an inline medication warning will appear if you attempt to prescribe or refill celecoxib, ibuprofen, meloxicam, or piroxicam in UCHealth's EHR. If the inline medication warning is visible, links to resources will be listed for your reference. There is patient education text available for UCHealth providers to use in discharge paperwork or the after visit summary (AVS).
Visit our Provider FAQs page here. For immediate questions, secure chat Groups: Pharmacogenomics Service in UCHealth's EHR.